MCID: CLL004
MIFTS: 15

Cellular Myxoid Liposarcoma

Categories: Cancer diseases, Gastrointestinal diseases, Oral diseases

Aliases & Classifications for Cellular Myxoid Liposarcoma

MalaCards integrated aliases for Cellular Myxoid Liposarcoma:

Name: Cellular Myxoid Liposarcoma 12
Round Cell Liposarcoma 12 69

Classifications:



External Ids:

Disease Ontology 12 DOID:5692
NCIt 47 C4252
SNOMED-CT 64 404070007 43296007
UMLS 69 C0334471

Summaries for Cellular Myxoid Liposarcoma

MalaCards based summary : Cellular Myxoid Liposarcoma, also known as round cell liposarcoma, is related to myxoid liposarcoma and liposarcoma. The drugs Trabectedin and Dacarbazine have been mentioned in the context of this disorder. Affiliated tissues include t cells.

Related Diseases for Cellular Myxoid Liposarcoma

Diseases related to Cellular Myxoid Liposarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

id Related Disease Score Top Affiliating Genes
1 myxoid liposarcoma 11.9
2 liposarcoma 10.5
3 fibrosarcoma 9.7
4 pemphigus 9.7
5 lichen planus 9.7
6 lichen planus pemphigoides 9.7
7 paraneoplastic pemphigus 9.7
8 myxofibrosarcoma 9.7

Graphical network of the top 20 diseases related to Cellular Myxoid Liposarcoma:



Diseases related to Cellular Myxoid Liposarcoma

Symptoms & Phenotypes for Cellular Myxoid Liposarcoma

Drugs & Therapeutics for Cellular Myxoid Liposarcoma

Drugs for Cellular Myxoid Liposarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 52)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Trabectedin Approved, Investigational Phase 3,Phase 2 114899-77-3 108150
2
Dacarbazine Approved, Investigational Phase 3 4342-03-4 5351166
3
Epirubicin Approved Phase 3 56420-45-2 41867
4
Etoposide Approved Phase 3 33419-42-0 36462
5
Gemcitabine Approved Phase 3 95058-81-4 60750
6
Ifosfamide Approved Phase 3 3778-73-2 3690
7
Mechlorethamine Approved Phase 3 51-75-2 4033
8
Docetaxel Approved May 1996, Investigational Phase 3 114977-28-5 148124 9877265
9 Alkylating Agents Phase 3,Phase 2,Phase 1
10 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
11 Anti-Bacterial Agents Phase 3,Phase 2
12 Antibiotics, Antitubercular Phase 3,Phase 2
13 Anti-Infective Agents Phase 3,Phase 2
14 Antimetabolites Phase 3
15 Antimetabolites, Antineoplastic Phase 3
16 Antimitotic Agents Phase 3
17 Antineoplastic Agents, Phytogenic Phase 3
18 Antiviral Agents Phase 3
19 Etoposide phosphate Phase 3
20 Isophosphamide mustard Phase 3
21 Topoisomerase Inhibitors Phase 3
22
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
23
Cyclophosphamide Approved, Investigational Phase 2,Phase 1 50-18-0, 6055-19-2 2907
24
Everolimus Approved Phase 2 159351-69-6 6442177
25
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
26
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
27
Efatutazone Investigational Phase 2 223132-37-4
28 Antiemetics Phase 2
29 Anti-Inflammatory Agents Phase 2
30 Antineoplastic Agents, Hormonal Phase 2
31 Autonomic Agents Phase 2
32 BB 1101 Phase 2
33 Dexamethasone acetate Phase 2 1177-87-3
34 Gastrointestinal Agents Phase 2
35 glucocorticoids Phase 2
36 HIV Protease Inhibitors Phase 2
37 Hormone Antagonists Phase 2
38 Hormones Phase 2
39 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2
40 Peripheral Nervous System Agents Phase 2
41
protease inhibitors Phase 2
42 Antibodies Phase 2
43 Antibodies, Monoclonal Phase 2
44 Immunoglobulins Phase 2
45 insulin Phase 2
46 Insulin, Globin Zinc Phase 2
47 Mitogens Phase 2
48 Antirheumatic Agents Phase 2,Phase 1
49 Antifungal Agents Phase 2
50 Interferon-alpha

Interventional clinical trials:

(show all 12)

id Name Status NCT ID Phase Drugs
1 Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy Recruiting NCT01710176 Phase 3 epirubicin 60 mg/m2/day (days 1, 2) and ifosfamide 3 g/m2/day (days 1, 2, 3);gemcitabine 900 mg/m2 (days 1 and 8) and docetaxel 75 mg/m2 (day 8);trabectedin 1.3 mg/m2;high-dose ifosfamide 14 g/m2, given in in 14 days;etoposide 150 mg/m2/day (days 1, 2, 3) and ifosfamide 3g/m2/day (days 1, 2, 3);gemcitabine 1800 mg/m2 (day 1) and dacarbazine 500 mg/m2 (day 1)
2 Brostallicin Clinical Trial for Myxoid Liposarcoma Unknown status NCT00633165 Phase 2 Brostallicin
3 Safety and Efficacy Study of Trabectedin for the Treatment of Localized Myxoid / Round Cell Liposarcoma Completed NCT00579501 Phase 2 Trabectedin;Dexamethasone
4 A Study of R1507 in Participants With Recurrent or Refractory Sarcoma Completed NCT00642941 Phase 2 RG1507
5 A Pilot Study of NY-ESO-1ᶜ²⁵⁹T Cells in Subjects With Advanced Myxoid/ Round Cell Liposarcoma Recruiting NCT02992743 Phase 1, Phase 2
6 Efatutazone Dihydrochloride in Treating Patients With Previously Treated Myxoid Liposarcoma That Cannot Be Removed by Surgery Recruiting NCT02249949 Phase 2 efatutazone
7 Sirolimus and Cyclophosphamide in Metastatic or Unresectable Myxoid Liposarcoma and Chondrosarcoma Recruiting NCT02821507 Phase 2 sirolimus and cyclophosphamide
8 Trial of CMB305 and Atezolizumab in Patients With Sarcoma Active, not recruiting NCT02609984 Phase 2
9 Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter Trial Terminated NCT01876043 Phase 2 plitidepsin
10 Autologous T Cells and Cyclophosphamide in Treating Patients With Soft Tissue Sarcoma That is Metastatic or Cannot Be Removed By Surgery Completed NCT01477021 Phase 1 cyclophosphamide
11 NY-ESO-1 Specific T Cells After Cyclophosphamide in Treating Patients With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma Withdrawn NCT02059850 Phase 1 Cyclophosphamide
12 Recombinant Interferon Gamma in Treating Patients With Soft Tissue Sarcoma Recruiting NCT01957709

Search NIH Clinical Center for Cellular Myxoid Liposarcoma

Genetic Tests for Cellular Myxoid Liposarcoma

Anatomical Context for Cellular Myxoid Liposarcoma

MalaCards organs/tissues related to Cellular Myxoid Liposarcoma:

39
T Cells

Publications for Cellular Myxoid Liposarcoma

Variations for Cellular Myxoid Liposarcoma

Expression for Cellular Myxoid Liposarcoma

Search GEO for disease gene expression data for Cellular Myxoid Liposarcoma.

Pathways for Cellular Myxoid Liposarcoma

GO Terms for Cellular Myxoid Liposarcoma

Sources for Cellular Myxoid Liposarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....